Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. (EGRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
EGRX · revenue · updated Jun 10, 2026
Core revenue metrics
Trailing 12 monthsEagle Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Eagle Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Eagle Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Eagle Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EGRX revenue · 4 questionsEGRX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Eagle Pharmaceuticals, Inc. SEC filings · GAAP · Eagle Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026